CNS adverse effects of opioids in cancer patients

CNS Drugs

Volumn 8, Issue 1, 1997, Pages 21-37

  Ripamonti, Carla ^a   Bruera, Eduardo ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b GREY NUNS COMMUNITY HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CISAPRIDE; CYCLIZINE; DEXAMPHETAMINE; DOMPERIDONE; FENTANYL; HALOPERIDOL; HYDROMORPHONE; LAXATIVE; METHYLPHENIDATE; METOCLOPRAMIDE; MORPHINE; NALOXONE; OPIATE; PETHIDINE; PROCHLORPERAZINE; PROMETHAZINE; PSYCHOSTIMULANT AGENT; SCOPOLAMINE;

AGITATION; ARTICLE; CANCER PAIN; CANCER PATIENT; CENTRAL NERVOUS SYSTEM DISEASE; COGNITIVE DEFECT; DELIRIUM; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE; EPIDEMIOLOGY; HALLUCINATION; HUMAN; HYPERALGESIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LONG TERM CARE; NAUSEA; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; TRANSDERMAL DRUG ADMINISTRATION; VOMITING; WITHDRAWAL SYNDROME;

EID: 0030751984     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708010-00003     Document Type: Article

References (151)

1. Foley KM. The treatment of cancer pain. N Engl J Med 1984; 313: 84-95
2. Cleeland CS, Bruera E. Pain and symptom management. In: Love R, editor. Manual of clinical oncology. 6th ed. New York: Springer-Verlag, 1994: 556-69
3. Ellison NM. Opioid analgesics for cancer pain: toxicities and their treatments. In: Patt RB, editor. Cancer pain. Philadelphia: J.B. Lippincott Company, 1993: 185-94
4. Sjogren P, Eriksen J. Opioid toxicity. Curr Opin Anaesth 1994; 7: 465-9
5. World Health Organization. Cancer pain relief and palliative care. Report of a WHO Expert Committee. Geneva: World Health Organization, 1993
6. Bruera E, Macmillan K, Hanson J, et al. Palliative care in a cancer center: results in 1984 versus 1987. J Pain Sympt Manage 1990; 5 (1): 1-5
7. Bruera E, Fox R, Chadwick S, et al. Changing patterns in the treatment of pain and other symptoms in advanced cancer patients. J Pain Symptom Manage 1987; 2 (3): 139-45
8. Leipzig RM, Goodman H, Gray G, et al. Reversible, narcotic-associated mental status impairment in patients with meta-static cancer. Pharmacology 1987; 35: 47-54
9. MacDonald N, Der L, Allan S, et al. Opioid hyperexcitability: the application of alternate opioid therapy. Pain 1993; 53: 353-5
10. Parkinson SK, Bailey SL, Little WL, et al. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology 1990; 72: 743-5
11. Sjogren P, Jonsson T, Jensen N-H, et al. Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine. Pain 1993; 55: 93-7
12. Sjogren P, Banning AM, Christensen CB, et al. Continuous reaction time after single dose, long-term oral and epidural opioid administration. Eur J Anaesthesiol 1994; 11: 95-100
13. Bruera E, Macmillan K, Hanson J, et al. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989; 39: 13-6
14. Vainio A, Ollila J, Matikainen E, et al. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995; 346: 667-70
15. Banning A, Sjogren P, Kaiser F. Reaction time in cancer patients receiving peripherally acting analgesics alone or in combination with opioids. Acta Anaesthesiol Scand 1992; 36: 480-2
16. Banning A, Sjogren P. Cerebral effects of long-term oral opioids in cancer patients measured by continuous reaction time. Clin J Pain 1990; 6: 91-5
17. Saarialho-Kere U, Mattila MJ, Paloheimo M, et al. Psychomotor, respiratory and neuroendocrinological effects of buprenorphine and amitriptyline in healthy volunteers. Eur J Clin Pharmacol 1987; 33: 139-46
18. MacDonald FC, Gough KJ, Nicoll RAG, et al. Psychomotor effects of ketorolac in comparison with buprenorphine and diclofenac. Br J Pharmacol 1989; 27: 453-9
19. Sjogren P, Banning A, Pain, sedation and reaction time during long-lerm treatment of cancer patients with oral and epidural opioids. Pain 1989; 39: 5-11
20. Sjogren P, Banning AM, Larsen TK, et al. Postural stability during long-term treatment of cancer patients with epidural opioids. Ada Anaesthesiol Scand 1990; 34: 410-2
21. Gordon N. Reaction-limes of methadone treated ex-heroin addicts. Psychopharmacologia 1976; 16: 337-44
22. Lombardo WK, Lombardo B, Goldstein A. Cognitive functioning under moderate and low dosage methadone maintenance. Int J Addict 1976; 11: 389-401
23. Rothenberg S, Schottenfeld S, Meyer RH, et al. Performance differences between addicts and non-addicts. Psychopharmacology 1977; 52: 299-307
24. Joo S. Methadone substitution and driver ability: research findings and conclusions from a discussion of experts. J Traffic Med 1994; 22: 101-3
25. Bruera E, Fainsinger RL, Schoeller T, et al. Rapid discontinuation of hypnotics in terminal cancer patients: a prospective study. Ann Oncology 1996; 7: 855-6
26. Bruera E, Chadwick S, Weinlick A, et al. Delirium and severe sedation in patients with terminal cancer. Cancer Treat Rep 1987; 71 (7/8): 787-8
27. Osborne R, Joes S, Slevin M. Morphine intoxication in renaf failure: the role of morphine-6-glucuronide. BMJ 1986; 292: 1548-9
28. Osborne R, Joel S, Trew D, et al. Morphine and metabolite behaviour after different routes of morphine administration: demonstration of the importance of the active metabolite morphine-6-glucuronide. Clin Pharmacol 1990; 47: 12-9
29. Fainsinger R, Miller MJ, Bruera E. Morphine intoxication during acute reversible renal insufficiency. J Palliat Care 1990: 8 (2): 52-3
30. Fainsinger R, Schoeller T, Briskin M, et al. Cognitive failure and coma after renal failure in a patient receiving captopril and hydromorphone. J Palliat Care 1993; 3: 53-5
31. Bruera E, Brenneis C, Paterson AHG, et al. Use of methylphenidate as an adjuvant to narcotics analgesics in patients with advanced cancer. J Pain Symptom Manage 1989; 4: 3-6
32. Bruera E, Brenneis C, Chadwick S, et al. Methylphenidate associated with narcotics for the treatment of cancer pain. Cancer Treat Rep 1987; 71: 67-70
33. Wilwerding MB, Loprinzi CL, Mailliard JA, et al. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotics. Support Care Cancer 1995; 3: 135-8
34. Yee JD, Berde CB. Dextroamphetamine or methylphenidate as adjuvants to opioid analgesia for adolescents with cancer. J Pain Symptom Manage 1994; 9: 122-5
35. Allan SG. Nausea and vomiting. In: Doyle D, Hanks GW, MacDonald N. editors. Oxford textbook of palliative medicine. Oxford: Oxford Medical Publications, 1993: 282-90
36. Clarke RS. Nausea and vomiting. Br J Anaesth 1984; 56: 19-27
37. Blancquaert JP, LeFebvre RA, Willems JL. Emetic and antiemetic effects of opioids in the dog. Eur J Rheumatol 1986; 128: 143-50
38. Ventafridda V, Oliveri E, Caraceni A, et al. A retrospective study on the use of oral morphine in cancer pain. J Pain Symptom Manage 1987; 2: 77-81
39. Peroutka SJ, Snyder SH. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982; I: 658-9
40. Hagen NA, Foley KM, Cerbhone DJ, et al. Chronic nausea and morphine-6-glucuronide. J Pain Symptom Manage 1991; 6: 125-8
41. Florez J, McCarty LE, Borison HL. A comparative study in the cat of the respiratory effects of morphine injected intravenously and into the cerebrospinal fluid. J Pharmacol Exp Ther 1968; 163: 448-55
42. Inturrisi CE. Management of cancer pain: pharmacology and principles of management. Cancer 1989; 63: 2308-20
43. Ling G, Spiegel K, Nishimura SL, et al. Dissociation of morphine's analgesic and respiratory depressant actions. Eur J Pharmacol 1983; 86: 487-8
44. Ling G, Spiegel K, Lockhart S, et al. Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J Pharmacol Exp Ther 1985; 232 (1): 149-55
45. Walsh TD. Opiates and respiratory function in advanced cancer. Recent Results Cancer Res 1984; 89: 115-7
46. Hanks GW, Twycross RG, Lloyd JW. Unexpected complication of successful nerve block. Anaesthesia 1981; 36: 37
47. Wells CJ, Lipton S, Lahuerta J. Respiratory depression after percutaneous cervical anterolateral cordotomy in patients on slow-release oral morphine [letter]. Lancet 1984; 1: 739
48. Paix A, Coleman A, Lees J, et al. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995; 63: 263-9
49. Sjogren P, Jakobsen S, Valentin N. Respiratory depression during epidural morphine treatment. Acta Anaesthesiol Scand 1991; 35: 553-5
50. Hunt G, Bruera E. Respiratory depression in a patient receiving oral methadone for cancer pain. J Pain Symptom Manage 1995; 10: 401-4
51. Langlade A, Serrie A, Sandouk P, et al. Levels of morphine and metabolites in CSF during respiratory depression after intraventricular morphine injection. Pain 1991; 44: 175-8
52. Peat SJ, Hanna MH, Woodham M, et al. Morphine-6-glucuronide: effects on ventilation in normal volunteers. Pain 1991; 43: 101-4
53. Hasselstrom J, Berg U, Lofgren A, et al. Long lasting respiratory depression induced by morphine-6-glucuronide? Br J Clin Pharmacol 1989; 27: 515-8
54. Paulus DA, Paul WL, Munson ES. Neurologic depression after intrathecal morphine. Anesthesiology 1981; 54: 517-8
55. Davies GK, Tolhurst-Cleaver CL, Terry LJ. CNS depression from intrathecal morphine. Anesthesiology 1980; 52: 280-1
56. Lobato RD, Madrid JL, Fatela LV, et al. Intraventricular morphine administration for intractable cancer pain: rationale, methods, clinical results. Acta Anaesthesiol Scand 1987; 31 Suppl. 85: 68-74
57. Obbens EAMT, Hill CS, Leavens ME, et al. Intraventricular morphine administration for control of chronic cancer pain. Pain 1987; 28: 61-8
58. Glynn CJ, Mather LE, Cousins MJ, et al. Spinal narcotics and respiratory depression. Lancet 1979; I: 356-7
59. Christensen V. Respiratory depression after extradural morphine. Br J Anaesth 1987; 52: 841-2
60. Scott DB, McLure J. Selective epidural analgesia. Lancet 1979; I: 1410-1
61. Rane A, Sawe J, Pacifici GM, et al. Regio-selective glucuronidation of morphine and interactions with benzodiazepines in human liver. Adv Pain Res Ther 1984; 8: 1297-300
62. Jacqz E, Ward S, Johnson R, et al. Extrahepatic glucuronidation of morphine in the dog. Drug Metab Dispos 1986; 14: 627-30
63. Dahlstrom BE, Paalzow LK. Pharmacokinetic interpretation of the enterohepatic recirculation and first-pass elimination of morphine in the rat. J Pharmacokinetic Biopharm 1978; 6: 506-19
64. Hanks GW, Hoskin PJ, Aherne GW, et al. Entero-hepatic circulation of morphine. Lancet 1988; I: 469-71
65. Gong Q-L, Hedner J, Bjorkman R, et al. Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48: 249-55
66. Bortolussi R, Fabiani F, Savron F, et al. Acute morphine intoxication during high-dose recombinant interleukin-2 treatment for metastatic renal cell cancer. Eur J Cancer 1994; 30A (12): 1905-7
67. Bruera E, Miller L, McCallion J, et al. Cognitive failure (CF) in patients with terminal cancer: a prospective study. J Pain Symptom Manage 1992; 7 (4): 192-5
68. Stiefel F, Fainsinger R, Bruera E. Acute confusional states in patients with advanced cancer. J Pain Symptom Manage 1992; 7 (2): 54-6
69. Fainsinger R, Young C. Palliative care round: cognitive failure in a terminally ill patient. J Pain Symptom Manage 1991; 6 (8): 492-4
70. Lipowski ZJ. Update on delirium. Psychiatr Clin North Am 1992; 15: 335-46
71. Folstein MF, Folstein S, McHugh PR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychosom Res 1975; 12: 189-98
72. Smith MJ, Breitbart WS, Platt MM. A critique of instruments and methods to detect, diagnose, and rate delirium. J Pain Symptom Manage 1995; 10 (1): 37-77
73. Brizer D, Manning D. Delirium induced by poisoning with anti-cholinergic agents. Am J Psychiatry 1982; 139 (10): 1343-4
74. Tune LE, Carr S, Hoag E, et al. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992; 149: 1393-4
75. 2 blocker delirium. Psychosomatics 1995; 36 (1): 74-7
76. Goodwin JS, Regan M. Cognitive dysfunction associated with naproxen and buprofen in the elderly. Arthritis Rheum 1982; 25 (8): 1013-5
77. Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989; 7 (5): 479-91
78. Baile WF. Neuropsychiatric disorders in cancer patients. Curr Opin Oncology 1996; 8: 182-7
79. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995; 10: 378-84
80. de Stoutz ND, Tapper M, Fainsinger R. Reversible delirium in terminally ill patients. J Pain Symptom Manage 1995; 10: 249-53
81. Ventafridda V, Ripamonti C, De Conno F, et al. Antidepressants increase bioavailability of morphine in cancer patients [letter]. Lancet 1987; I: 1204
82. McQuay HJ, Carroll D, Faura CC, et al. Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 1990; 48: 236-44
83. Caraceni A, Martini C, DeConno F, et al. Organic brain syndromes and opioid administration for cancer pain. J Pain Symptom Manage 1994; 9: 527-33
84. Lowe GR. The phenomenology of hallucinations as an aid to differential diagnosis. Br J Psychiatry 1973; 123: 621-33
85. Bruera E, Miller MJ, Macmillan K, et al. Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain 1992; 48: 163-6
86. Massie MJ, Holland JC. The cancer patient with pain: psychiatric complications and their management. J Pain Symptom Manage 1992; 7: 99-109
87. Levine PM, Silberfarb PM, Lipowski ZJ. Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer 1978; 42: 1385-91
88. Bruera E, Spachynski K, MacEachern T, et al. Cognitive failure in cancer patients in clinical trials. Lancet 1993; 341: 247-8
89. Folstein MF, Felting JH, Lobo A, et al. Cognitive assessment of cancer patients. Cancer 1984; Suppl. 10: 2250-7
90. Yue M, Fainsinger R, Bruera E. Cognitive impairment in a patient with a normal mini-mental state examination (MMSE). J Pain Symptom Manage 1994; 9: 51-3
91. Marsden CD, Hallet M, Fahns S. The nosology and pathophysiology of myoclonus. In: Marsden CD, Fahns S, editors. Movement disorders. London: Butterworth, 1982: 196-248
92. Frenk H, Watkins LR, Mayer DJ. Differential behavioral effects induced by intrathecal microinjection of opiates: comparison of convulsive and cataleptic effects produced by morphine, methadone, and D-ala2-methionine-enkephalinamide. Brain Res 1984; 299: 31-42
93. Glavina MJ, Robertshaw R. Myoclonic spasms following intrathecal morphine. Anaesthesia 1988; 43: 389-90
94. De Conno F, Caraceni A, Martini C, et al. Hyperalgesia and myoclonus with intrathecal infusion of high-dose morphine. Pain 1991; 47: 337-9
95. Krames ES, Gershow Y, Glassberg A. Continuous infusion of spinally administered narcotics for the relief of pain due to malignant disorders. Cancer 1985; 56: 696-702
96. Glare PA, Walsh TD, Pippenger CE. Normorphine, a neurotoxic metabolite? Lancet 1990; 335: 725-6
97. Sjogren P, Dragsted L. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993; 37: 780-2
98. Eisele JH, Grigsby EJ, Dea G. Clonazepam treatment of myoelonic contractions associated with high-dose opioids: case report. Pain 1992; 49: 231-2
99. Babul N, Darte AC. Putative role of hydromorphone metabolites in myoclonus [letter]. Pain 1993; 51: 260-1
100. Szeto HH, Inturrisi CE, Houde R, et al. Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 1977; 86: 738-41
101. Kaiko RF, Foley KM, Grabinski PY, et al. Central nervous system excitatory effects of meperidine in cancer patients. Ann Neurol 1983; 13: 180-5
102. Hochman MS. Meperidine-associated myoclonus and seizures in long-term hemodialysis patients [letter]. Ann Neurol 1983; 14 (5): 27
103. Bowdle TA. Myoclonus following sufentanil without EEG seizure activity. Anesthesiology 1987; 67: 593-5
104. Rao T, Mummaneni N. Convulsions: an unusual response to intravenous fentanyl administration. Anesth Analg 1982; 61: 1020-1
105. Tommasino C, Maekawa T, Shapiro HM. Fentanyl-induced seizures activate subcortical brain metabolism. Anesthesiology 1984; 60: 283-90
106. Pasternack GW, Bodmar RJ, Clark JA, et al. Morphine-6-glucuronide, a potent new agonist. Life Sci 1987; 41: 2845-9
107. Labella FS, Pinsky C, Havlicek V. Morphine derivates with diminished opiate receptor potency enhanced central excitatory activity. Brain Res 1979; 174: 263-71
108. Hagen N, Thirlwell MP, Dhaliwal HS, et al. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glucuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 1995; 35: 37-44
109. Babul N, Hagen N, Baker T. Hydromorphone metabolite: accumulation in renal failure. J Pain Symptom Manage 1995; 10 (3): 184-6
110. Potter JM, Reid DB, Shaw RJ, et al. Myoclonus associated with treatment with high doses of morphine: the role of supplemental drugs. BMJ 1989; 299: 150-3
111. International Association for the Study of Pain Subcommittee on Taxonomy. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. Pain 1986; 3: 217-9
112. Sjogren P, Jensen N-H, Jensen T-S. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain 1994; 59: 315-6
113. Ali NMK. Hyperalgesic response in a patient receiving high concentrations of spinal morphine [letter]. Anesthesiology 1986; 65: 449
114. Stillman MJ, Moulin DE, Foley KE. Paradoxical pain following high-dose spinal morphine [abstract]. Pain 1987; 4: S389
115. Yaksh TL, Harty GJ. Pharmacology of the allodynia in rats evoked by high-dose intrathecal morphine. J Pharmacol Exp Ther 1987; 244: 501-7
116. Woolf CJ. Intrathecal high dose morphine produces hyperalgesia in the rat. Brain Res 1981; 209: 491-5
117. Bruera E, Kuehn N, Miller MJ, et al. The Edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7: 6-9
118. Bruera E, Schoeller T, Wenk R, et al. A prospective multicenter assessment of the Edmonton Staging System for cancer pain. J Pain Symptom Manage 1995; 10: 348-55
119. Ewing J. Detection alcoholism: the CAGE Questionnaire. JAMA 1984; 252: 1905-7
120. Lawlor P, Walker P, Bruera E. Severe opioid toxicity in a cancer patient coping chemically with psychosocial suffering. J Pain Symptom Manage. In press
121. Robinson K, Bruera E. The management of pain in patients with advanced cancer: the importance of multidimensional assessments. J Palliat Care 1995; 11: 51-3
122. Coyle N, Breitbart W, Weaver S. Delirium as a contributing factor to 'crescendo' pain: three case reports. J Pain Symptom Manage 1994; 9: 44-7
123. Ripamonti C, Rodriguez C. Gastrointestinal motility disorders in advanced cancer patients. In: Portenoy RK, Bruera E, editors. Supportive care medicine. New York: Oxford University Press, 1996. In press
124. Wamsley JK, Lewis MS, Young WS, et al. Autoradiographic localisation of muscarinic cholinergic receptors in rat brainstem. J Neurosci 1981; 1: 176-91
125. 1-receptors in the rat brain: an autoradiographic study. Neuroscience 1981; 6: 15-7
126. Bradberry JC, Raebel MA. Continuous infusion of naloxone in the treatment of narcotic overdose. Drug Intell Clin Pharm 1981; 15: 945-7
127. Citron ML. How would you treat narcotic overdoses in cancer patients? Drug Therapy 1984; 9: 85-7
128. Osborne RJ, Joel SP, Trew D, et al. Analgesic activity of morphine-6-glucuronide [letter]. Lancet 1988; 2: 188
129. Forrest W, Brown B, Brown C, et al. Dextroamphetamine with morphine for the treatment of postoperative pain. New Engl J Med 1977; 296: 712-5
130. Kreeger L, Duncan A, Cowap J. Psychostimulants used for opioid-induced drowsiness. J Pain Symptom Manage 1996; 11 (1): 1-2
131. Bruera E, Fainsinger R, MacEachern T, et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates: a preliminary report. Pain 1992; 50: 75-7
132. Bruera E, Watanahe S. Psychostimulants as adjuvant analgesics. J Pain Symptom Manage 1994; 9: 412-5
133. Fernandez F, Adams F, Levy JK, et al. Cognitive impairment due to AIDS-related complex and its response to psychostimulants. Psychosomatics 1988; 29: 38-46
134. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am 1992; 15 (1): 191-222
135. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153: 231-7
136. Settle EC, Ayd FJ. Haloperidol: a quarter century of experience. J Clin Psychiatry 1983; 44: 440-8
137. Bottomley DM, Hanks GW. Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 1990; 5: 259-61
138. De Sousa E, Jepson BA. Midazolam in terminal care. Lancet 1988; I: 67-8
139. Morley JS, Miles JB, Bowsher D. Paradoxical pain [letter]. Lancet 1992; 340: 1045
140. Smith MT, Walt JA, Cramond T. Morphine-3-glucuronide: a potent antagonist of morphine analgesia. Life Sci 1990; 47: 579-85
141. Zaw Tun N, Bruera E. Active metabolites of morphine. J Palliat Care 1992; 8: 48-50
142. Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady state concentrations and the consequences of renal failure. Pain 1991; 47: 13-9
143. Eisendrath SJ, Goldman B, Douglas J, et al. Meperidine-induced delirium. Am J Psychiatry 1987; 144: 1062-5
144. Steimberg RB, Gilman DE, Johnson III F. Acute toxic delirium in a patient using transdermal fentanyl. Anesth Analg 1992; 75: 1014-6
145. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain 1997; 70: 109-15
146. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone and morphine. Cancer 1996; 78 (4): 852-7
147. Fainsinger RL, MacEachern T, Miller MJ, et al. The use of hypodermoclysis for rehydration in terminally ill cancer patients. J Pain Symptom Manage 1994; 9: 298-302
148. Billings JA. Comfort measures for the terminally ill: is dehydration painful? J Am Geriatr Soc 1985; 33: 808-10
149. Printz LA. Is withholding hydration a valid comfort measure in the terminally ill? Geriatrics 1988; 43: 84-8
150. Musgrave CF. Terminal dehydration: to give or not to give intravenous fluids? Cancer Nursing 1990; 13: 62-6
151. Yan E, Bruera E. Case report: parenteral hydration of terminally ill cancer patients. J Palliat Care 1991; 7: 40-3